Peptides for Depression: Emerging Research and What We Know

Depression is one of the most common and debilitating mental health conditions worldwide, affecting over 280 million people according to the World Health Organization. Standard treatments — including SSRIs, SNRIs, cognitive behavioral therapy, and other evidence-based psychiatric interventions — remain the cornerstone of depression management and have decades of clinical trial data supporting their use. Nothing in this article should be interpreted as a suggestion to replace those treatments.

That said, researchers have begun investigating whether certain peptides may influence neurobiological pathways relevant to depression. Some of these peptides modulate neurotransmitter systems, promote neuroplasticity, or address secondary factors like sleep disruption and neuroinflammation that contribute to depressive symptoms. The research is early (largely preclinical) but it represents an area of growing scientific interest.

A critical note before we go further: If you are experiencing depression, the most important step you can take is to work with a psychiatrist, therapist, or other qualified mental health professional. Peptides are not FDA-approved treatments for depression, and the evidence discussed below comes primarily from animal studies and limited human data. They should never be used as a primary treatment and should only be considered as a potential complement to standard care, under medical supervision.

Key takeaways

• Peptides are not replacements for antidepressants, therapy, or psychiatric care. Anyone with depression should be working with a qualified mental health professional
• Selank shows anxiolytic and antidepressant properties in preclinical research through GABAergic modulation and enkephalin enhancement
• Semax upregulates BDNF, a mechanism shared with several established antidepressants, and has neuroprotective properties
• BPC-157 modulates dopaminergic and serotonergic systems and has shown preclinical antidepressant-like effects in animal models
• Most evidence is from animal studies, and no peptide has undergone the rigorous Phase III clinical trials required for FDA approval as a depression treatment

Table of contents

1. Important disclaimer: peptides and mental health
2. How depression works at the neurobiological level
3. Selank: GABAergic modulation and enkephalins
4. Semax: BDNF and neuroplasticity
5. BPC-157: dopamine, serotonin, and preclinical findings
6. DSIP: sleep architecture and the depression-insomnia cycle
7. Thymosin Alpha 1: neuroinflammation and immune-mediated depression
8. Why peptides cannot replace standard treatment
9. FAQ
10. Sources

Important disclaimer: peptides and mental health

Depression is a serious medical condition that carries real risks, including suicidal ideation. Effective, well-studied treatments exist. SSRIs, SNRIs, psychotherapy (particularly CBT and interpersonal therapy), and in severe cases, interventions like ECT and ketamine-assisted therapy, have strong clinical evidence behind them.

The peptides discussed in this article are in early stages of research. None have been approved by the FDA or any major regulatory body for the treatment of depression. The decision to explore peptides as a complementary approach should only be made in consultation with a psychiatrist or mental health provider who is aware of your full treatment history.

If you are in crisis, please contact the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room.

How depression works at the neurobiological level

Understanding why certain peptides are being studied for depression requires a brief overview of the neurobiology involved. Depression is not simply a “chemical imbalance.” It involves multiple interacting systems.

Neurotransmitter dysregulation

The monoamine hypothesis (that depression results from deficiencies in serotonin, norepinephrine, and dopamine) drove antidepressant development for decades. SSRIs and SNRIs work by increasing the availability of these neurotransmitters in the synaptic cleft. While this model is oversimplified, these neurotransmitter systems remain central to both depression and anxiety pathology [1].

Neuroplasticity and BDNF

Brain-derived neurotrophic factor (BDNF) supports the survival and growth of neurons and promotes synaptic plasticity, the brain’s ability to form new connections. BDNF levels are consistently found to be lower in people with depression, and successful antidepressant treatment tends to increase BDNF levels [2]. This is relevant because some peptides directly upregulate BDNF expression.

Neuroinflammation

A subset of people with depression show elevated inflammatory markers including IL-6, TNF-alpha, and C-reactive protein. This “inflammatory depression” subtype may be particularly resistant to standard antidepressants and may respond to interventions that target immune dysregulation [3]. Hormonal transitions such as perimenopause in women over 40 can also contribute to depressive symptoms through estrogen-related changes in neurotransmitter function.

Sleep disruption

Depression and insomnia have a bidirectional relationship. Poor sleep worsens depressive symptoms, and depression disrupts sleep architecture, particularly reducing slow-wave sleep and altering REM patterns. Addressing sleep can meaningfully improve depression outcomes [4].

These four pathways (neurotransmitter signaling, BDNF-mediated neuroplasticity, neuroinflammation, and sleep disruption) are the mechanisms through which various peptides may exert effects relevant to depression.

Selank: GABAergic modulation and enkephalins

Selank is a synthetic peptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analogue of tuftsin, an immunomodulatory peptide naturally produced by the spleen. Selank has been approved in Russia as an anxiolytic medication (see our guide on peptides for anxiety for more on its anxiolytic properties), though it has no regulatory approval in the United States or Europe for any indication.

Mechanism of action

Selank’s primary mechanism involves modulation of the GABAergic system, the same inhibitory neurotransmitter system targeted by benzodiazepines, but without the sedation or dependence risk associated with that drug class. A 2021 pharmacology review in the Journal of Clinical Pharmacology provided a detailed overview of selank’s GABAergic mechanisms and its place among sedative-hypnotic agents [16]. It influences GABA-A receptor function and increases the stability of enkephalins, endogenous opioid peptides involved in mood regulation and stress response [5].

Enkephalins play an underappreciated role in depression. They modulate the brain’s reward and stress circuits, and their depletion has been linked to anhedonia, the inability to feel pleasure that is a hallmark symptom of depression [6]. By inhibiting enkephalinase (the enzyme that breaks down enkephalins), selank may help maintain higher levels of these mood-regulating peptides.

Research findings

A 2008 study published in the Bulletin of Experimental Biology and Medicine found that selank produced anxiolytic effects comparable to medazepam (a benzodiazepine) in animal models, but also demonstrated distinct antidepressant-like properties in the forced swim test, a standard preclinical model for antidepressant activity [5]. Unlike benzodiazepines, selank did not impair motor coordination or produce sedation.

Gene expression studies have shown that selank influences the expression of 36 genes involved in GABAergic neurotransmission, suggesting a broad modulatory effect on inhibitory signaling rather than a simple receptor agonism [7]. A 2018 review of selank’s molecular biology further characterized the heptapeptide’s anxiolytic and potential antidepressant mechanisms at the receptor level [18]. This may explain why its effects appear more varied than those of single-target medications.

Limitations

Most selank research comes from Russian institutions, and peer review standards vary. The forced swim test, while widely used, is an imperfect model for human depression. Human clinical data on selank’s antidepressant effects specifically (as opposed to its anxiolytic effects) is limited, and it has not undergone the large-scale, placebo-controlled trials that would be required for FDA approval.

Semax: BDNF and neuroplasticity

Semax is a synthetic analogue of adrenocorticotropic hormone (ACTH) fragments 4-10, also developed in Russia. It has been approved there as a neuroprotective agent, primarily for stroke recovery and cognitive enhancement. Its relevance to depression centers on its ability to upregulate BDNF.

Mechanism of action

Semax increases BDNF expression in the hippocampus and prefrontal cortex, the same brain regions where BDNF deficits are most associated with depression [8]. This is significant because BDNF upregulation is increasingly understood to be a downstream mechanism of how conventional antidepressants work. SSRIs, for example, take 2-4 weeks to produce clinical effects, and this delay is thought to correspond to the time required for BDNF-mediated neuroplastic changes [2].

Semax also modulates the expression of nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF), both of which support neuronal health and may be relevant to the neurodegenerative aspects of chronic depression [9]. A 2020 functional connectomic study demonstrated that both selank and semax produce measurable changes in brain network connectivity, providing neuroimaging-level evidence that these peptides have meaningful central nervous system effects [17].

Research findings

A 2007 study in Doklady Biological Sciences demonstrated that semax increased BDNF mRNA expression in the rat hippocampus by up to 1.4-fold within one hour of administration and sustained elevated levels for 24 hours [8]. This rapid and sustained BDNF upregulation is notable because it mirrors the timeline seen with newer rapid-acting antidepressants like ketamine.

Semax has also shown cognitive-enhancing effects in human studies, improving attention, memory, and mental clarity in patients recovering from stroke [10]. While cognitive enhancement is not the same as antidepressant activity, the cognitive dulling associated with depression (“brain fog”) is a significant component of functional impairment, and addressing it can improve quality of life.

Limitations

Semax has not been studied in clinical trials specifically for depression. The BDNF connection is mechanistically logical but remains indirect, since increasing BDNF does not automatically translate to antidepressant effects. Most human data comes from stroke recovery contexts, not psychiatric populations. The leap from “increases BDNF” to “treats depression” requires clinical evidence that does not yet exist.

BPC-157: dopamine, serotonin, and preclinical findings

BPC-157 is primarily known for musculoskeletal healing, but its effects extend into the central nervous system. Multiple preclinical studies have documented its interactions with dopaminergic and serotonergic neurotransmitter systems, the same systems targeted by most antidepressant medications.

Mechanism of action

BPC-157 modulates dopamine system activity, including interactions with D2 receptors and the nigrostriatal pathway. It also influences serotonin metabolism and has been shown to counteract the behavioral effects of serotonin-depleting agents in animal models [11]. A 2019 psychiatric review noted that BPC-157 “may be better for depressive symptoms” compared to some other peptides under investigation, based on its broad neurotransmitter modulation [12].

The peptide also demonstrates effects on the nitric oxide (NO) system, which plays a role in both neurotransmission and neuroinflammation. NO dysregulation has been independently linked to depression, and BPC-157’s ability to modulate this system may represent an additional relevant mechanism [11].

Research findings

In the forced swim test and tail suspension test (standard preclinical depression models), BPC-157 has demonstrated antidepressant-like effects, reducing immobility time in a manner comparable to established antidepressant drugs [11]. It has also been shown to counteract behavioral despair induced by chronic mild stress protocols, which more closely model the sustained nature of human depression than acute stress tests.

BPC-157 has additionally shown the ability to reverse the behavioral effects of dopamine-depleting and serotonin-depleting agents, suggesting it may help restore neurotransmitter balance rather than simply increasing levels of one neurotransmitter [11]. This is an interesting distinction from SSRIs, which primarily affect serotonin.

Limitations

All antidepressant data for BPC-157 comes from animal models. The forced swim test has been criticized as measuring stress coping rather than depression per se. No human studies have examined BPC-157’s effects on depressive symptoms. The “may be better for depressive symptoms” characterization from the psychiatric review, while worth noting, is based on preclinical data extrapolation.

For more on BPC-157’s mechanisms and broader research, see our full BPC-157 guide.

DSIP: sleep architecture and the depression-insomnia cycle

Delta sleep-inducing peptide (DSIP) is a nine-amino-acid neuropeptide first isolated from rabbit brain in 1977. Its relevance to depression lies in its ability to normalize sleep architecture, specifically promoting the deep, restorative slow-wave sleep that is often disrupted in depressive disorders.

The depression-sleep connection

Up to 90% of people with major depression report sleep disturbances. These are not just symptoms. They are mechanistically involved in maintaining the depressive state. Disrupted slow-wave sleep impairs the brain’s overnight consolidation processes, reduces the clearance of metabolic waste (including inflammatory markers), and perpetuates fatigue and cognitive impairment [4].

Standard antidepressants often worsen sleep quality, particularly SSRIs, which tend to suppress REM sleep and can cause insomnia. This creates a treatment paradox where the medication addressing depression simultaneously worsens one of its most debilitating symptoms.

How DSIP may help

DSIP appears to normalize the ratio of sleep stages rather than simply inducing sedation. In studies on individuals with disrupted sleep, DSIP administration promoted more time in slow-wave sleep and more normalized sleep architecture without the “hangover” effect associated with sleeping medications [13]. By addressing the sleep disruption component of depression, DSIP may help break the insomnia-depression cycle.

For a deeper discussion of peptides that address sleep, see our guide on peptides for sleep.

Limitations

DSIP research peaked in the 1980s and 1990s, and relatively few modern studies have revisited it with current methodology. The peptide has a short half-life in circulation, which presents practical challenges for sustained effects. No studies have specifically examined DSIP as an adjunct to antidepressant therapy for depression-related insomnia.

Thymosin Alpha 1: neuroinflammation and immune-mediated depression

Thymosin alpha 1 (Ta1) is an immune-modulating peptide naturally produced by the thymus gland. It is FDA-approved in several countries (though not the US) for hepatitis B and as an immune adjunct in cancer therapy. Its connection to depression involves the growing understanding that chronic inflammation can drive depressive symptoms in a subset of patients.

Neuroinflammation and depression

Approximately 25-30% of people with major depression show elevated inflammatory markers. This subgroup tends to respond poorly to standard antidepressants but may respond to anti-inflammatory interventions [3]. The mechanism involves peripheral inflammatory cytokines crossing the blood-brain barrier and activating microglia, the brain’s resident immune cells, which then produce local neuroinflammation that disrupts neurotransmitter metabolism and neuroplasticity.

How Thymosin Alpha 1 may be relevant

Ta1 modulates immune function by promoting T-cell maturation and balancing pro-inflammatory and anti-inflammatory cytokine production [14]. By reducing systemic inflammation, it may indirectly address the neuroinflammatory component of depression in those patients where inflammation is a contributing factor.

A 2020 review in Frontiers in Immunology discussed the bidirectional relationship between immune function and mood disorders, noting that immune-modulating peptides like Ta1 represent a “theoretically promising but clinically unproven” approach to inflammation-driven depression [15].

Limitations

Ta1 has not been studied directly for depression in any clinical trial. The inflammation-depression connection, while supported by substantial evidence, applies to a subset of depressed patients, not all. Identifying who has “inflammatory depression” requires specific testing (CRP, IL-6 levels), and even then, the evidence that reducing inflammation reliably improves mood is mixed. This is among the most speculative applications discussed in this article.

Why peptides cannot replace standard treatment

This point warrants its own section because it is essential. The peptides discussed above interact with neurobiological systems relevant to depression, but interacting with relevant systems is not the same as being an effective treatment.

Standard antidepressants and psychotherapy have been tested in thousands of randomized controlled trials involving millions of patients. They have known response rates, established safety profiles, drug interaction data, and long-term outcome studies. None of the peptides discussed here have any of that.

Depression also carries acute risks, including suicidality, that require proven, reliable interventions. Experimenting with unproven peptides while delaying or discontinuing evidence-based treatment could have serious consequences.

If you and your mental health provider are interested in exploring peptides as a complementary approach alongside standard treatment, that is a conversation worth having. But it is not a decision to make alone, and it is not a substitute for the treatments we know work. For more context on peptide therapy in general, including how it integrates with conventional medicine, see our introductory guide.

FAQ

Can peptides cure depression?▼

No. No peptide has been shown to cure depression in human clinical trials. Depression is a complex condition that typically requires ongoing management with evidence-based treatments including therapy, medication, lifestyle modifications, and social support. Peptides are being researched for potential complementary roles, but they are far from established treatments.

What is the best peptide for depression?▼

There is no “best peptide for depression” because none are proven treatments. Based on preclinical data alone, selank and semax have the most directly relevant research: selank for its GABAergic and enkephalin effects, semax for BDNF upregulation. BPC-157 has interesting neurotransmitter modulation data. However, ranking peptides for an indication where none have clinical proof is premature and potentially misleading.

Are peptides safer than antidepressants?▼

This is not a meaningful comparison at present. Antidepressants have extensive safety data from decades of use in millions of patients, so we know their side effects, interactions, and risks in detail. Peptides like selank and semax have far less safety data, particularly for long-term use. “Fewer known side effects” is not the same as “safer”; it may simply reflect less study. Do not discontinue prescribed antidepressants in favor of peptides.

Can I use peptides alongside my antidepressant?▼

This is a question for your prescribing physician or psychiatrist, not something to decide independently. Some peptides may interact with medications that affect the same neurotransmitter systems. For example, combining serotonin-modulating peptides with SSRIs raises theoretical concerns about serotonin syndrome. Any complementary peptide use should be disclosed to and monitored by your mental health provider.

How long would peptides take to help with depression symptoms?▼

This cannot be answered reliably because controlled human data does not exist. In preclinical studies, effects on behavior were observed within days to weeks, but animal behavioral models are poor predictors of human treatment timelines. For context, standard antidepressants typically require 4-8 weeks to show full effects, and the neurobiological timelines involved (BDNF upregulation, neuroplastic changes) suggest that any peptide affecting similar pathways would require comparable durations.

Is selank approved for depression anywhere?▼

Selank is approved in Russia as an anxiolytic (anti-anxiety) medication, not specifically as an antidepressant. It has no regulatory approval in the United States, Europe, or most other countries for any indication. Russian regulatory standards differ from FDA requirements, and approval in one country does not imply equivalence to approval elsewhere.

Sources

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55-68. doi:10.1056/NEJMra073096

2. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127. doi:10.1016/j.biopsych.2006.02.013

3. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. doi:10.1038/nri.2015.5

4. Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008;10(3):329-336. doi:10.31887/DCNS.2008.10.3/dnutt

5. Seredenin SB, Kozlovskaia MM, Blednov IuA, et al. The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction. Zh Vyssh Nerv Deiat Im I P Pavlova. 1998;48(1):153-160.

6. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000;25(2):195-200. doi:10.1038/76061

7. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.

8. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108

9. Agapova TIu, Agniullin IaV, Silachev DN, et al. Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex. Mol Genet Mikrobiol Virusol. 2008;(3):28-32.

10. Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40.

11. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990-2001. doi:10.2174/1381612824666180608101119

12. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8

13. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. doi:10.1159/000117964

14. Tuthill C, Rios I, McBeath R. Thymalfasin: clinical pharmacology and antiviral and immune-modulating activities. Ann N Y Acad Sci. 2010;1194:179-189. doi:10.1111/j.1749-6632.2010.05395.x

15. Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci. 2019;1437(1):57-67. doi:10.1111/nyas.13712

16. Sedative-Hypnotic Agents: Focus on Selank. J Clin Pharmacol. 2021. PubMed

17. Functional Connectomic Approach to Selank and Semax Effects. Dokl Biol Sci. 2020. PubMed

18. Peptide-based Anxiolytics: The Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018. PubMed